WHO ICTRP trial
A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of…
NL-OMON39884 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON39884 |
|---|---|
| Public title | A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator*s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma |
| Scientific title | A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator*s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma - LUMIERE C14012- PTCL |
| Primary sponsor | Millenium Pharmaceuticals |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Australia;Austria;Belgium;Brazil;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Mexico;Netherlands ;New Zealand;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation… |
| Conditions | Peripheral T-cel lymphoma;10025321;Peripheral T-cel lymphoma |
| Interventions | Patients will be randomized (1:1) to study treatment, Arm A (alisertib) or Arm B (selected single-agent comparator: pralatrexate or gemcitabine). ;Alisertib;Peripheral-T-Cell Lymphoma (PTCL);Phase 3 |
| Registration date | Jun 2, 2014 |
| Target size | 4 |
| Secondary IDs | 2011-003545-18;NCT01482962;NL39566.068.12 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: